United Therapeutics Corporation announced that its subsidiary, Lung Bioengineering Inc. (LBE), completed its 500th lung transplant utilizing its centralized ex vivo lung perfusion (EVLP) service. This significant milestone was achieved in September 2024.
The EVLP service has evaluated over 800 donated lungs since its inception in 2014, leading to these 500 successful transplants. This technology plays a crucial role in increasing the availability of transplantable lungs by reconditioning and assessing donor organs that might otherwise be deemed unsuitable.
This achievement underscores United Therapeutics' commitment to addressing the critical shortage of transplantable organs and advancing its broader organ manufacturing initiatives. The continued success and expansion of the EVLP service contribute to the company's long-term vision in regenerative medicine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.